Jaguar Health Q2 net loss $12.2M, revenue $2.7M (+36% QoQ); OnTarget Phase 3 topline due late Oct

Jaguar Health, Inc.

2023-Q2 EPS reported -$1.42

Net loss attributable to shareholders $12.2M in Q2 2023 vs $9.4M in Q2 2022; diluted EPS ($0.42) vs ($0.12).
Combined net revenue for Mytesi and Canalevia-CA1 $2.7M, up 36% QoQ but down 8% YoY.
Loss from operations increased to $8.1M from $6.5M YoY; R&D spend rose to $4.3M from $2.5M.
Mytesi prescription volume up 4% sequentially; Canalevia-CA1 net revenue $39K (+40% QoQ).
Top line results from Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea expected late October 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Jaguar Health, Inc. reported second quarter 2023 results: revenue approximately $2.7 million.

Period: second quarter 2023
Revenue: approximately $2.7 million
Result: reported results

Exact text from the filing

was approximately $2.7 million in the second quarter of 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-091022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.